摘要
目前大多数给药方式通常为长期循环,这样有利于在靶组织积累。对李子进行有效的表面改性设计,可确定了其较长的循环时间和靶向能力。优化合成方案,有效地结合靶向分子和元素,增加循环时间具有很大挑战性,同时需要几个功能元素几乎是不可能的。另一方面,在过去的十年中,仿生技术的发展在增加粒子的安全性,生物相容性和靶向性,同时保持合成方案简单和可重复性等方面提出了新方法。最近,我们开发了一种新的药物输送系统,被称为leukolike向量(LLV)的免疫细胞生物,由纳米多孔硅芯和白细胞的细胞膜形成的壳组成。本研究的目的是探讨LLV蛋白质含量。本文报道了LLV的蛋白质组学分析, 并证明本研究方法使用超过150白细胞膜蛋白用于修改合成颗粒表面特性,以确定粒子对发炎的内皮细胞的安全性,循环时间和靶向能力。
关键词: 仿生掩饰,药物输送,白细胞,白细胞样载体,膜,纳米技术,纳米微粒,蛋白质组学。
图形摘要
Current Drug Targets
Title:Proteomic Profiling of a Biomimetic Drug Delivery Platform
Volume: 16 Issue: 13
Author(s): Claudia Corbo, Alessandro Parodi, Michael Evangelopoulos, David A. Engler, Rise K. Matsunami, Anthony C. Engler and Roberto Molinaro, Shilpa Scaria, Francesco Salvatore and Ennio Tasciotti
Affiliation:
关键词: 仿生掩饰,药物输送,白细胞,白细胞样载体,膜,纳米技术,纳米微粒,蛋白质组学。
摘要: Current delivery platforms are typically designed for prolonged circulation that favors superior accumulation of the payload in the targeted tissue. The design of efficient surface modifications determines both a longer circulation time and targeting abilities of particles. The optimization of synthesis protocols to efficiently combine targeting molecules and elements that allow for an increased circulation time can be challenging and almost impossible when several functional elements are needed. On the other hand, in the last decade, the development of bioinspired technologies was proposed as a new approach with which to increase particle safety, biocompatibility and targeting, while maintaining the synthesis protocols simple and reproducible. Recently, we developed a new drug delivery system inspired by the biology of immune cells called leukolike vector (LLV) and formed by a nanoporous silicon core and a shell derived from the leucocyte cell membrane. The goal of this study is to investigate the protein content of the LLV. Here we report the proteomic profiling of the LLV and demonstrate that our approach can be used to modify the surface of synthetic particles with more than 150 leukocyte membraneassociated proteins that determine particle safety, circulation time and targeting abilities towards inflamed endothelium.
Export Options
About this article
Cite this article as:
Claudia Corbo, Alessandro Parodi, Michael Evangelopoulos, David A. Engler, Rise K. Matsunami, Anthony C. Engler and Roberto Molinaro, Shilpa Scaria, Francesco Salvatore and Ennio Tasciotti , Proteomic Profiling of a Biomimetic Drug Delivery Platform, Current Drug Targets 2015; 16 (13) . https://dx.doi.org/10.2174/1389450115666141109211413
DOI https://dx.doi.org/10.2174/1389450115666141109211413 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Key microRNAs Regulated the Development of Non-small Cell Lung Cancer by Targeting TGF-β-induced epithelial–mesenchymal Transition
Combinatorial Chemistry & High Throughput Screening Meeting Report: The Fourth Annual PepTalk Meeting: The Human Proteome
Current Proteomics Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Cartilage Regeneration Using Adipose-Derived Stem Cells
Current Stem Cell Research & Therapy DNAM-1 (CD226): A Two-Sword Fencer for Innate and Adaptive Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The DREAM of Pain Relief
Current Rheumatology Reviews Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Therapeutic Potential and Pharmaceutical Applications of <i>Cucurbita</i>
Current Nutrition & Food Science Characteristic Alterations of Nuclear Structure and Chromatin Organisation of Cancer Cells Addressed by Proteome Analysis**
Current Proteomics Vitamin D Analogs in Cutaneous Malignancies
Current Pharmaceutical Design Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets Nitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of Cocaine
CNS & Neurological Disorders - Drug Targets Primary Tumors of the Sacrum: Imaging Findings
Current Medical Imaging Studies of p53 Tumor Suppression Activity in Mouse Models
Current Genomics Pharmacogenomics of Cytochrome P450 Enzymes in Tumours
Current Pharmacogenomics Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry GCPII Imaging and Cancer
Current Medicinal Chemistry LDH Nanocontainers as Bio-Reservoirs and Drug Delivery Carriers
Recent Patents on Nanotechnology The Use of the Bone Seeking Radiopharmaceutical 153-Samarium-EDTMP as an Adjuvant Treatment for Osteosarcoma: A Review
Current Medical Imaging